Clinical And Regulatory RisksClinical and regulatory risks are present for rosnilimab, ANB032, ANB033, and ANB101 in the development of immune cell modulating antibodies.
Financial Performance1Q operating expenses were 16% higher than consensus estimates, indicating cost pressures.
Market CompetitionCompetitor Lilly's peresolimab showed limited depth of response, indicating potential for rosnilimab to outperform.